Estimation the Association Between SerumFibulin-1 Levels and Diabetic Nephropathy
DOI:
https://doi.org/10.24237/04.04.679Keywords:
Diabetic nephropathy Fibulin-1 Biomarkers Chronic kidney disease Fenal dysfunctionAbstract
Abstract
Background: One of the most dangerous side effects of diabetes is diabetic nephropathy, which can result in end-stage renal failure. Fibulin-1, an extracellular matrix component, is believed to be involved in renal and vascular disorders. The purpose of this study was to assess the connection between the onset of diabetic nephropathy and plasma fibulin-1 levels.
Methods: There were 90 individuals in the trial, 40 of whom were healthy controls and 50 of whom had diabetic nephropathy. Glycated hemoglobin (HbA1c), creatinine, urea, components of the lipid profile (total cholesterol, triglycerides, high density lipoprotein "HDL" and low density lipoprotein "LDL"), and fibulin-1 levels were among the biochemical studies performed on blood samples. SPSS version 26.0 and Graph Pad Prism version 6 were used to analyze the data.
Results: The results showed that diabetic nephropathy patients had significantly higher levels of fibulin-1,fasting blood glucose, glycated hemoglobin, creatinine, urea, and LDL compared to the control group (p < 0.001). A positive correlation was observed between plasma fibulin-1 levels and creatinine and LDL, while there was no significant relationship between fibulin-1 and HbA1c or BMI was observed.
The diagnostic potential with Receiver operating characteristic curve analysis of fibulin-1, for patients, revealing very good area under the curve(0.848, p< 0.001) with good sensitivity (70 %) and excellent specificity (95 %).
Conclusion: The fibulin-1 increased significantly (p <0.001) in diabetic nephropathy patients with very good area under the curve(0.848). for this results fibulin-1may be a possible indicator of diabetic nephropathy progression, given its association with markers of renal dysfunction.
Downloads
References
1[1]
W. M. Valencia, H. Florez, "How to prevent the microvascular complications of type 2 diabetes beyond glucose control" Bmj, 356(2017), DOI: https://doi.org/10.1136/bmj.i6505
[2]
N. R. Burrows, I. Hora, L. S. Geiss, E. W. Gregg, A. Albright, “Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes—United States and Puerto Rico, 2000–2014”, MMWR. Morbidity and mortality weekly report, 66., 1165–1170(2017), DOI: http://dx.doi.org/10.15585/mmwr.mm6643a2
[3]
N. Samsu, “Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment”, BioMed research international, 2021(1), 1497449(2021)., DOI: https://doi.org/10.1155/2021/1497449
[4]
M. K. Ali, K. M. Bullard, S. Saydah, G. Imperatore, E. W. Gregg, “Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014”, The lancet Diabetes & endocrinology, 6(5), 392-403(2018), DOI: https://doi.org/10.1016/S2213-8587(18)30027-5
[5]
H. M. Al-Nadawi, & W. Y. M. Al-Dulaimy, “Serum Selenium Levels: Correlation with Inflammatory Biomarkers and Oxidative Stress in Diabetic Nephropathy”, Medical Forum Monthly, 35(12), (2024), DOI: https://doi.org/10.60110/medforum.351207
[6]
J. Kopel, C. Pena-Hernandez, & K. Nugent, “Evolving spectrum of diabetic nephropathy”, World journal of diabetes, 10(5), 269(2019), DOI: http://dx.doi.org/10.4239/wjd.v10.i5.269
[7]
J. Donate-Correa, D. Luis-Rodríguez, E. Martín-Núñez, V. G. Tagua, C. Hernández-Carballo, C. Ferri, J. F. Navarro-González, “Inflammatory targets in diabetic nephropathy”, Journal of Clinical Medicine, 9(2), 458(2020), DOI: https://doi.org/10.3390/jcm9020458
[8]
J. Lu, X. Liu, S. Jiang, S. Kan, Y. An, C. Zheng, G. Xie, “Body mass index and risk of diabetic nephropathy: a Mendelian randomization study”, The Journal of Clinical Endocrinology & Metabolism, 107(6), 1599-1608(2022), DOI: https://doi.org/10.1210/clinem/dgac057
[9] Y. Sang, K. M. Mao, Y. Huang, X. F. Wu, X. F. Wang, L. Ruan, C. T. Zhang, “Relationship between the plasma fibulin-1 levels, pulse wave velocity, and vascular age in asymptomatic hyperuricemia”, Current Medical Science, 41, 94-99(2021), DOI: https://doi.org/10.1007/s11596-021-2324-3
[10] R. Timpl, T. Sasaki, G. Kostka, & M. L. Chu, “Fibulins: a versatile family of extracellular matrix proteins”, Nature reviews Molecular cell biology, 4(6), 479-489(2003), DOI: https://doi.org/10.1038/nrm1130
[11] S. De Vega, T. Iwamoto, & Y. Yamada, “Fibulins: multiple roles in matrix structures and tissue functions”, Cellular and molecular life sciences, 66, 1890-1902(2009), DOI: https://doi.org/10.1007/s00018-009-8632-6
[12] A. Scholze, E. M. Bladbjerg, J. J. Sidelmann, A. C. Diederichsen, H. Mickley, M. Nybo, L. M. Rasmussen, “Plasma concentrations of extracellular matrix protein fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes”, Cardiovascular diabetology, 12, 1-7(2013), DOI: https://doi.org/10.1186/1475-2840-12-6
[13] M. Neiman, J. J. Hedberg, P. R. Donnes, I. Schuppe-Koistinen, S. Hanschke, R. Schindler, P. Nilsson, “Plasma profiling reveals human fibulin-1 as candidate marker for renal impairment”, Journal of proteome research, 10(11), 4925-4934(2011), DOI: https://doi.org/10.1021/pr200286c
[14] A. Inci, O. Akin, H. Y. Ellidag, E. Eren, S. Dolu, F. Sari, “Fibulin levels in autosomal dominant polycystic kidney disease and its relationship to arterial stiffness”, Clinical laboratory, 63(11), 1869-1874(2017), DOI : https://doi.org/10.7754/Clin.Lab.2017.170617
[15] Y. M. Sun, Y. Su, J. Li, & L. F. Wang, “ Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy”, Biochemical and biophysical research communications, 433(4), 359-361(2013), DOI: https://doi.org/10.1016/j.bbrc.2013.02.120
[16] K. P. Mishra, A. L. O. K. Mawar, P. K. Kare, N. I. S. H. A. Verma, “Relationship between fasting blood glucose, serum urea, serum creatinine and duration of diabetes in Type-2 diabetic patients”, Flora Fauna, 21(1), 127-32(2015).
[17] G. P. Senthilkumar, M. S. Anithalekshmi, M. Yasir, S. Parameswaran, R. muthuPackirisamy, Z. Bobby, “Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic nephropathy” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 12(1), 23-26(2018), DOI: https://doi.org/10.1016/j.dsx.2017.08.005
[18] M. A. Shaaban, M. A. E. R. Korany, R. M. A. El-Shazly, M. A. N. Ibrahem, “Assessment of Serum (YKL-40) As an Early Diagnostic Marker of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus”, The Egyptian Journal of Hospital Medicine, 81(5), 2071-2077(2020), DOI: https://doi.org/10.21608/ejhm.2020.126404
[19] G. T. Russo, S. De Cosmo, F. Viazzi, A. Pacilli, A. Ceriello, S. Genovese, & AMD-Annals Study Group, “Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD annals initiative” Diabetes Care, 39(12), 2278-2287(2016), DOI: https://doi.org/10.2337/dc16-1246
Downloads
Published
Issue
Section
License
Copyright (c) 2026 CC BY 4.0
This work is licensed under a Creative Commons Attribution 4.0 International License.
